Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VH4011499 Dose A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1 Dose A - Fasted condition | EXPERIMENTAL | VH4011499 Dose A tablet administered in fasted condition. |
| Part 1 Dose A- Fed condition (high fat meal) | EXPERIMENTAL | VH4011499 Dose A tablet administered in fed condition (high fat meal). |
| Part 2 Dose B - Optional - Fed condition (low fat meal) | EXPERIMENTAL | VH4011499 Dose B tablet administered in fed condition (low fat meal). |
| Part 3 Dose B - Fasted condition | EXPERIMENTAL | VH4011499 Dose B tablet administered in fasted condition. |
| Part 3 Dose B - Fed condition (high fat meal) | EXPERIMENTAL | VH4011499 Dose B tablet administered in fed condition (high fat meal). |
| Name | Type | Description |
|---|---|---|
| VH4011499 Dose A | DRUG | VH4011499 administered in fasted or fed conditions. |
| VH4011499 Dose B | DRUG | VH4011499 Dose B administered in fasted or fed conditions. |
Inclusion Criteria: * Participants who are 18 to 55 years of age. * Participants who are overtly healthy. * One SARs-CoV-2 negative test is required prior to dosing * Body weight within 50-100 kg and body mass index (BMI) within the range 19-32 kg/m2 (inclusive). * Capable of giving signed informed...
Top 20 of 28 competitors
VH4011499 Dose A is an investigational small molecule being studied for the treatment of HIV infections. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities. The drug is being evaluated in clinical trials to assess its safety and pharmacokinetics.
VH4011499 Dose A is being developed by GSK plc, a biopharmaceutical company listed on the stock exchange under the ticker symbol GSK. The company is conducting clinical research to evaluate the drug's potential as a treatment for HIV infections.
VH4011499 Dose A is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory authority. The drug is being studied in healthy volunteers to evaluate its safety and how it is processed by the body.
VH4011499 Dose A has been studied in one completed Phase 1 clinical trial, identified as NCT06368986. This trial, conducted in the United States, enrolled 60 healthy participants to investigate the effect of food on the bioavailability of a capsid inhibitor (CAI) in male and female healthy participants.
VH4011499 Dose A is a small molecule that acts as a capsid inhibitor (CAI). It is being developed to target HIV infections by interfering with the viral capsid, a protein shell that protects the viral genetic material. This mechanism is intended to disrupt the virus's ability to replicate and infect cells.